List view / Grid view
17 December 2015 | By Victoria White
GBI Research says the treatment market for pancreatic cancer is set to grow from its current level of $1.9 billion to an impressive $2.9 billion by 2021, driven primarily by an increased prevalence of the disease...
15 December 2015 | By Victoria White
GBI Research’s latest report states that pharmaceutical companies are considering various strategies to overcome the challenge of rising R&D costs, with deal-making the foremost method of boosting short-term revenues...
10 December 2015 | By Victoria White
According to business intelligence provider GBI Research, the global immunology treatment market is set to expand from $61.5 billion in 2015 to reach $74.2 billion in 2022...
3 December 2015 | By Victoria White
GBI Research says the market will rise at a steady CAGR of 2.9% from $9.2 billion in 2014 to $11.2 billion in 2021...
24 November 2015 | By Victoria White
GBI Research says this rise will be driven by the uptake of recently approved and pipeline premium products, as well as the rapidly expanding treatment population...
17 November 2015 | By Victoria White
GBI Research says that the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, will drive the market...
13 November 2015 | By Victoria White
GBI Research says the rise will be driven primarily by growth in disease prevalence due to an aging global population...
20 October 2015 | By Victoria White
The treatment market for multiple myeloma across China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021...
8 September 2015 | By Victoria White
This increase will be driven primarily by the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, says GBI Research...
20 August 2015 | By Victoria White
The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, says GBI Research...
23 July 2015 | By Victoria White
The global market for type 2 diabetes mellitus therapeutics will rise in value from $23.5 billion in 2014 to an estimated $39 billion by 2021, driven primarily by rising disease prevalence and the continued uptake of recently approved and emerging branded treatments, according to business intelligence provider GBI Research.
15 July 2015 | By Victoria White
The anti-hypertensive therapeutics market in the Asia-Pacific will expand in value from $15.7b in 2014 to reach $19.9b by 2021, says GBI Research...
30 June 2015 | By Victoria White
The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, according to GBI Research...
17 June 2015 | By Victoria White
The pancreatic cancer treatment pipeline is dominated by early-stage development, meaning many therapies are unlikely to reach the market in the near future...
2 June 2015 | By Victoria White
The rheumatoid arthritis therapeutics market in the Asia-Pacific (APAC) region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 3.3%, according to business intelligence provider GBI Research.
